Bria-IMT Combo Shows Survival in Phase 2 Breast Cancer Trial
In a phase 2 study, 52% of patients treated with Bria-IMT plus a checkpoint inhibitor for metastatic breast cancer were alive at one year.
Read More
Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma
The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and early antitumor activity.
How Antibody-Drug Conjugates Have Impacted HER2-Positive Breast Cancer Treatment
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Watch
Imbruvica-Venclexta Combination Demonstrates Benefits in Untreated CLL
Results from a four-year follow-up of a phase 3 trial determined that the combination of Imbruvica and Venclexta provided benefits for untreated patients with CLL.
Depression Can Impact Breast Cancer Treatment and Survival
Depression reduces the likelihood of receiving recommend treatment, which can affect survival, according to a Kentucky-based study of patients with breast cancer.
